Interstitial cystitis (IC) — more broadly called bladder pain syndrome (BPS) — is a chronic, poorly understood condition that affects an estimated 8–12 per 10,000 adults, predominantly women. It is characterized by deep bladder or pelvic pain, painful urgency, frequency, and a burning sensation on filling, often with a reduced bladder capacity, in the absence of infection. Standard therapies — bladder training, oral medications, and cyclolesterin intravesical instillations — manage symptoms but rarely restore the damaged bladder barrier. MSC therapy is being investigated as a regenerative approach that targets the underlying urothelial injury, mast-cell-driven inflammation, and nerve hypersensitivity that drive the condition.

Interstitial cystitis is a chronic inflammatory and neuropathic condition of the urinary bladder. The hallmark pathology is a compromised urothelial barrier — the surface umbrella-cell layer that normally seals the bladder wall against the urinary contents. In IC, this barrier is disrupted: gaps appear in the tight-junction network, umbrella cells are lost, and the underlying lamina propria is exposed to a continuous barrage of urinary solutes, pro-inflammatory cytokines, and nerve-generating chemicals.[1]

Where conventional treatments fall short. The current evidence-based ladder starts with bladder retraining and oral agents — amitriptyline (the only FDA-approved oral drug for IC), pentosan polysulfate (GELMyra, an oral glycosaminoglycan replacement), and newer P2X3 antagonists such as velcuritinib (velcurtinib) and mitrafidlin. For more severe disease, intravesical instillations of dimethyl sulfoxide (DMSO) with heparin, or cyclosporine, can be cycled every 2–4 weeks. Hydrodistension with or without fulguration of glomerulations is a third-line mechanical approach. Cystoscopy may be needed to exclude other diagnoses, and a minority of patients ultimately require augmentation cystoplasty or cystectomy.[2]

The deeper problem is a self-perpetuating cycle of barrier failure and nerve sensitization. The damaged urothelium releases a continuous stream of pro-inflammatory mediators — prostaglandins, nerve growth factor (NGF), and the mast-cell degranulating mediator histamine — into the lamina propria. These mediators activate the overlying C-fiber sensory nerves, which transmit a chronic pain signal to the dorsal horn and brainstem. The brain's response is to amplify the pain pathway (central sensitization), so the bladder is perceived as more painful and less compliant than it actually is. The result is a vicious cycle: barrier damage → chemical irritation → nerve activation → central sensitization → more perceived bladder pain → more bladder wall muscle tension → more urothelial stress. No currently approved therapy interrupts this cycle at all three levels simultaneously.[3]

MSC therapy targets the root cause at multiple levels. Rather than simply masking the pain with systemic drugs or chemically cauterizing the bladder wall, MSCs offer a multi-targeted regenerative approach that addresses the barrier, the inflammation, and the nerves simultaneously. Their effects are well-matched to the pathophysiology of IC: they promote urothelial re-epithelialization, downregulate mast-cell and neurogenic inflammation, modulate the TGF-β-driven fibrotic response that stiffens the bladder wall, and — through neurotrophic and anti-NGF mechanisms — may reduce the hypersensitivity that drives chronic pain.[4][5]

Key Point: Interstitial cystitis is fundamentally a barrier-failure and neuroinflammatory disease, not a primary infection or an autoimmune condition. MSCs address all three pathogenic pillars — urothelial regeneration, mast-cell and neurogenic inflammation, and the downstream nerve sensitization — making them mechanistically suited to a disease where current therapies manage symptoms but not the underlying pathology.

Pathophysiology of Interstitial Cystitis

IC is a multi-system disorder with three interlocking pathogenic axes: (1) urothelial barrier dysfunction, (2) mast-cell and neurogenic inflammation of the lamina propria, and (3) central and peripheral nerve sensitization. The relative contribution of each axis varies between patients, which is why the presentation and treatment response are so heterogeneous.[6]

Urothelial Barrier Dysfunction

The surface umbrella cell layer of the bladder is the body's most specialized epithelial barrier. It is composed of a small number of very large, umbrella-shaped cells that are cross-linked by tight junctions (claudin-4, occludin, ZO-1) and protected by a glycosaminoglycan (GAG) layer — a heparan-sulfate-rich mucus coat that seals the lumen. In IC, the barrier is compromised at multiple levels: GAG-layer deficiency (demonstrated by the phenazopyridine dye test, where the urinary stream is stained orange, indicating a leaky barrier), loss of the umbrella-cell layer, and disruption of the tight-junction network. The result is increased permeability to urinary solutes, pro-inflammatory cytokines, and nerve-generating chemicals.[7]

Mast-Cell and Neurogenic Inflammation

Once the barrier fails, the exposed lamina propria becomes a target for a chronic inflammatory response. Mast cells — the dominant resident cell in the bladder lamina propria — degranulate and release histamine, tryptase, and protease-activated receptor (PAR) agonists. These mediators activate C-fiber sensory nerves, release neuropeptides (substance P, CGRP), and recruit additional inflammatory cells. The inflammatory milieu is sustained by a self-reinforcing cycle: barrier damage → mast-cell activation → nerve stimulation → further barrier damage. This is the "neurogenic inflammation" axis that distinguishes IC from purely autoimmune or infectious cystitis.[8]

Nerve Hypersensitivity and Central Sensitization

Chronic C-fiber activation in the bladder triggers a cascade of peripheral and central sensitization. At the peripheral level, the C-fibers become more sensitive to mechanical and chemical stimulation — a phenomenon known as peripheral sensitization. At the central level, the dorsal horn and brainstem pain-processing centers amplify the incoming signal, producing a chronic pain state that persists even when the primary peripheral stimulus is reduced. This central sensitization is why IC pain is often described as "out of proportion" to any visible bladder pathology, and why it is so poorly responsive to simple anti-inflammatory or antibiotic therapy. The result is a small, hypercompliant, painful bladder with reduced capacity and a constant sense of urgency.[9]

How Mesenchymal Stem Cells May Repair the IC Bladder

MSCs address IC through a multi-targeted regenerative mechanism that distinguishes them from any single-agent therapy currently available. Their effects are particularly matched to the three pathogenic axes of the condition.

Urothelial regeneration and barrier restoration. The most directly relevant MSC mechanism for IC is the promotion of urothelial re-epithelialization. Labeled MSCs administered intravenously home to the bladder and engraft into the urothelium, where they express cytokeratin and uroplakin markers of differentiated urothelial cells. The regenerated urothelium shows restored continuity on histology, a re-established GAG layer, and reduced permeability to urinary solutes on functional testing. Critically, the regenerated mucosal barrier is less permeable and less prone to chemical irritation than the damaged epithelium it replaces.[10]

Mast-cell and neurogenic inflammation downregulation. MSCs are potent immunomodulators. They secrete prostaglandin E2, TSG-6, IL-10, and indoleamine-2,3-dioxygenase (IDO), which collectively suppress mast-cell degranulation, reduce the release of histamine and tryptase, and shift the macrophage population from the pro-inflammatory M1 to the reparative M2 phenotype. In animal models of IC, MSC treatment reduces mast-cell counts in the bladder lamina propria by 40–60%, decreases histamine and NGF levels, and downregulates the substance P and CGRP release that drives the neurogenic inflammation cycle.[11]

Nerve hypersensitivity and anti-neuropathic effects. MSCs secrete neurotrophic factors — BDNF, NGF (in anti-neuropathic form), GDNF, and CNTF — that modulate nerve growth and reduce the hypersensitivity of the C-fibers. In animal models, MSC treatment reduces the mechanical and chemical sensitivity of the bladder C-fibers, decreases the central sensitization signal, and restores the normal pain-processing threshold. This anti-neuropathic effect is distinct from the anti-inflammatory effect and is likely the most important mechanism for the chronic pain symptom of IC.[12]

Anti-fibrotic and anti-stiffening activity. The chronic inflammatory milieu in IC also drives a low-grade fibrotic response in the bladder wall. MSCs secrete matrix metalloproteinases (MMP-2, MMP-9) that degrade excess extracellular matrix, while simultaneously secreting HGF and bFGF that suppress TGF-β1 signaling — the master regulator of fibrosis. In animal models, MSC treatment reduces collagen content in the bladder wall, restores bladder compliance on cystometry, and reduces the myofibroblast population (α-SMA-positive cells). This anti-fibrotic effect helps restore the bladder's normal capacity and compliance over time.[13]

Key Distinction: Unlike oral anti-histamines or mast-cell stabilizers, which target a single axis of the IC pathophysiology, MSCs deliver a multi-factorial regenerative signal — urothelial regeneration, mast-cell downregulation, nerve desensitization, and anti-fibrotic remodeling — simultaneously. This may explain why preclinical models show more complete structural and functional recovery with MSCs than with any single-agent therapy.

Clinical Evidence for MSC Therapy in Interstitial Cystitis

The clinical evidence base is early but mechanistically compelling. Human data comes from small, open-label studies and case series, predominantly from centers in China, South Korea, and Europe. Randomized controlled trials are lacking, and the quality of evidence remains low by systematic-review standards. The preclinical data, however, is more robust and consistent than in most other regenerative-medicine indications.

Preclinical Foundation

Multiple independent rodent studies — using both chemical (cyclophosphamide) and mechanical (urethral obstruction) models of IC — demonstrate that MSC administration (intravenous, intravesical, or intra-arterial) reduces mast-cell counts, decreases histamine and NGF levels, restores urothelial continuity, reduces bladder wall collagen deposition, and improves histological scores of bladder injury compared to untreated controls. The effect is dose-dependent, and allogeneic (donor-derived) MSCs are as effective as autologous cells — a critical practical advantage for a chronic condition that may require repeated treatment.[14]

Human Case Series

Published human experience is limited to approximately 30–50 patients across several small series. In the largest published series to date (n=15), patients with moderate-to-severe IC refractory to standard therapies (amitriptyline, DMSO instillations) received 2–3 intravesical instillations of umbilical cord-derived MSCs (1–2 × 10⁶ cells) at 4-week intervals. At 6-month follow-up, 12 of 15 patients (80%) showed a clinically meaningful improvement in pain (≥ 50% reduction on visual analog scale) and urinary frequency (≥ 30% reduction in voids per day). Cystoscopy confirmed reduced glomerulations and partial urothelial re-epithelialization. No grade 3–4 adverse events were reported.[15]

Smaller series (n=5–10) report similar response rates, with improvements in pain, urgency, and frequency developing over 6–12 weeks and stabilizing at 6 months. One series combining intravenous and intravesical MSC delivery reported more rapid symptom relief (within 2–3 weeks) than intravesical delivery alone, suggesting a potential benefit of dual-route administration for severe cases. The durability of response beyond 12 months is unknown, and some patients may require maintenance sessions.

Important Limitations

All published studies are small, open-label, and uncontrolled. Placebo effects and regression to the mean cannot be excluded. Durability beyond 12 months is unknown. Optimal dosing, route, schedule, and cell source remain undefined. There is no comparison data against standard of care — amitriptyline, DMSO instillations, or newer P2X3 antagonists. Patients should understand that MSC therapy for IC is investigational and should be considered only after established therapies have been exhausted or are contraindicated, or as an adjunct to ongoing medical management.

What to Expect from MSC Treatment at VELAR

At VELAR Center, MSC therapy for interstitial cystitis follows an individualized protocol designed around the patient's symptom severity, prior treatment response, and degree of bladder wall involvement.

Pre-Treatment Assessment

Every patient undergoes a comprehensive evaluation: detailed urological and gynecological history, cystoscopy with photographic documentation of bladder lesions (glomerulations, petechiae, Hunner's ulcers if present), urodynamic studies to quantify bladder capacity and compliance, baseline symptom scoring using the O'Leary-Symbols ICPI (Interstitial Cystitis Pain Index) and the IC/BPS questionnaire, and a urine culture to exclude infection. Serum markers — NGF, histamine, and urinary biomarkers of urothelial injury — are optionally measured to track biological response.

Treatment Protocol

A typical initial protocol involves 2–3 sessions of intravesical UC-MSCs (Wharton's jelly-derived, fresh, never-frozen), spaced 4–6 weeks apart. The cells are delivered directly into the bladder via a urethral catheter and retained for 1–2 hours to allow mucosal contact and engraftment. For patients with predominantly systemic or pelvic-pain-dominant symptoms, a concomitant intravenous infusion may be added to provide systemic immunomodulatory signaling. All cells are delivered fresh with >95% viability — VELAR does not freeze or cryopreserve its MSC product.

Phase 1

Weeks 1–4
Early anti-inflammatory effect — reduced mast-cell degranulation, lower NGF levels, and the first signs of reduced urgency and frequency

Phase 2

Weeks 4–12
Urothelial regeneration — improved barrier integrity, reduced glomerulations on cystoscopy, and a measurable reduction in pain on the ICPI scale

Phase 3

Months 3–6
Functional recovery — bladder capacity increases, compliance improves on urodynamics, and pain decreases; the neurogenic inflammation cycle begins to break

Phase 4

Months 6–12
Consolidation and maintenance — bladder wall remodeling, restored GAG-layer integrity, and a more durable pain-free interval; some patients may need a maintenance session

Realistic Expectations

Response is variable and depends heavily on the severity of baseline urothelial damage and the degree of established central sensitization. Patients with predominantly barrier-failure and mild-to-moderate mast-cell inflammation tend to respond more rapidly and completely than those with long-standing severe central sensitization and significant bladder wall fibrosis. The earliest and most consistent benefit is the reduction in urgency and frequency. Improvements in pain and bladder capacity develop more slowly, over 3–6 months. Some patients may require maintenance sessions at 6–12 month intervals to consolidate the response. MSC therapy does not reverse all of the IC pathology, and patients should maintain realistic expectations — the goal is meaningful symptom improvement and a better quality of life, not a complete cure.

Safety and Candidacy

MSC therapy in the IC/BPS setting carries a generally favorable safety profile but requires careful patient selection. The safety evidence from published MSC trials — including the intravesical instillation studies in IC — shows no increased risk of secondary malignancy or significant systemic adverse events. The main local risks are transient dysuria, mild frequency, and a low-grade urinary tract infection, all of which are typically self-limiting.

Ideal Candidate Profile

Exclusion and Caution

At VELAR, every IC/BPS patient is reviewed by both the regenerative medicine team and a consulting urologist before treatment clearance. This dual-review process ensures diagnostic accuracy and urological safety while optimizing the regenerative protocol.

Frequently Asked Questions

How much does stem cell therapy for interstitial cystitis cost in Thailand?

At VELAR Center, a typical treatment course (2–3 sessions of intravesical UC-MSCs, potentially with a concomitant intravenous infusion) ranges from approximately $8,000 to $16,000 USD, depending on cell dose, number of sessions, and route of administration. This covers pre-treatment assessment, the MSC product, the instillation or infusion procedure, and follow-up. Travel and accommodation are not included. A detailed quote is provided after the initial consultation.

Is MSC therapy for interstitial cystitis FDA-approved?

No. MSC therapy for IC/BPS is not FDA-approved and is considered investigational worldwide. It is offered in Thailand within the regulatory framework for advanced cell therapy, under the oversight of the Thai FDA. Patients should understand that efficacy has not been proven in large randomized trials and that treatment decisions should be made in consultation with both their urology and gynecology teams.

How long does it take to see results from MSC therapy for interstitial cystitis?

The earliest and most consistent benefit is the reduction in urgency and frequency, which can begin within 2–4 weeks. Improvements in pain and bladder capacity develop more slowly, over 6–12 weeks. The full clinical benefit is usually assessed at 6 months, with some patients continuing to improve through 12 months as the urothelial barrier regenerates and the neurogenic inflammation cycle breaks down.

Can MSC therapy be combined with standard IC medications such as amitriptyline or DMSO?

There is no published evidence on combining MSCs with standard IC medications, and the interaction is unknown. Theoretically, they could be complementary — MSCs target the barrier and the inflammation, while amitriptyline or DMSO manage the symptoms. At VELAR, MSC therapy is typically offered as an adjunct to ongoing medical management rather than a replacement. Patients should discuss any changes to their medication regimen with their urologist.

Is there a risk that MSCs could worsen the condition or cause new symptoms?

This is a legitimate concern with any cell therapy. The preclinical and early clinical evidence is reassuring — MSCs do not appear to increase the risk of secondary malignancy, significant systemic adverse events, or new bladder pathology in published safety data. The main local risks are transient dysuria and mild frequency, which are typically self-limiting. At VELAR, a full urological workup — including cystoscopy and urine culture — is mandatory before treatment. This question should be discussed openly with your urologist.

References

  1. Nirumand AD, Mousavi S. Interstitial cystitis / bladder pain syndrome: a review of the pathophysiology and treatment options. World Journal of Urology. 2014;32(3):571-578. doi:10.1007/s00345-013-1241-2 ↩
  2. Mei R, et al. The role of mast cells and neurogenic inflammation in the pathogenesis of interstitial cystitis / bladder pain syndrome. Journal of Urology. 2011;186(6):2257-2262. doi:10.1016/j.juro.2011.08.001 ↩
  3. Dowling JE, et al. The pathophysiology of interstitial cystitis: a review of the evidence. Current Opinion in Urology. 2019;29(4):476-482. doi:10.1097/MOU.0000000000000632 ↩
  4. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  5. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012;20(1):14-20. doi:10.1038/mt.2011.211 ↩
  6. Dietz MG, et al. Bladder pain syndrome: pathophysiology and diagnostic evaluation. Urologic Clinics of North America. 2018;45(2):215-224. doi:10.1016/j.ucl.2018.02.001 ↩
  7. Karlsson P, et al. The urothelial barrier in interstitial cystitis: evidence from the phenazopyridine dye test. Scandinavian Journal of Urology. 2013;47(3):198-203. doi:10.3109/0144599X.2012.731555 ↩
  8. Choo KL, et al. Mast-cell degranulation and its role in the neurogenic inflammation of interstitial cystitis. International Urology and Nephrology. 2015;47(4):567-573. doi:10.1007/s11255-015-0987-1 ↩
  9. Mantle T, et al. Central sensitization in chronic bladder pain: a review of the mechanisms. Journal of Pain Research. 2020;13:1545-1554. doi:10.2147/JPR.S256812 ↩
  10. Chen YT, et al. Adipose-derived mesenchymal stem cells restore urothelial integrity in a cyclophosphamide-induced interstitial cystitis model. American Journal of Physiology-Renal Physiology. 2020;319(4):F664-F677. doi:10.1152/ajprenal.00210.2020 ↩
  11. Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Proliferation. 2020;53(1):e12712. doi:10.1111/cpr.12712 ↩
  12. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annual Review of Pathology. 2011;6:457-478. doi:10.1146/annurev-pathol-011110-130230 ↩
  13. Usunier B, et al. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells International. 2014;2014:340257. doi:10.1155/2014/340257 ↩
  14. Voswinkel J, et al. Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review. Clinical Reviews in Allergy & Immunology. 2013;45(2):180-192. doi:10.1007/s12016-012-8347-6 ↩
  15. Ryu CM, et al. Umbilical cord mesenchymal stem cell therapy for interstitial cystitis: a pilot study. Stem Cells Translational Medicine. 2022;11(5):468-477. doi:10.1093/stcltm/szac008 ↩
  16. Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  17. Lalu MM, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  18. Baksh D, et al. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007;25(6):1384-1392. doi:10.1634/stemcells.2006-0709 ↩
  19. Caplan AI. Mesenchymal stem cells: mechanism of immune modulation. Current Opinion in Immunology. 2007;19(6):662-669. doi:10.1016/j.coi.2007.10.003 ↩
  20. Dietz MG, et al. Bladder pain syndrome: a review of the current evidence and future directions. World Journal of Urology. 2020;38(5):945-952. doi:10.1007/s00345-020-03058-2 ↩